Latest news
ATAGI recommendations on use of the Moderna and Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccines
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of XBB 1.5 COVID-19 vaccines.
ATAGI update additional 2023 COVID-19 vaccination dose
The Australian Technical Advisory Group on Immunisation (ATAGI) recently updated their advice for the COVID-19 booster dose.
ATAGI Update on the COVID-19 Vaccination Program
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) regarding an additional COVID-19 dose for highest risk people in 2023. These recommendations are in addition to the previous ATAGI COVID-19 vaccine booster advice published in February 2023.
ATAGI advice on the preferential use of bivalent COVID-19 vaccines for primary vaccination of people aged 12 years or older
ATAGI has made recommendations on the use of bivalent COVID-19 vaccines as a primary course.
ATAGI recommendations on use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine.
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine.
ATAGI recommendations on use of the Pfizer COVID-19 vaccine for children aged 6 months to 4 years
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Pfizer COVID-19 vaccine for children aged 6 months to 4 years (Pfizer 6 months to 4 years).
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine.
ATAGI update on boosters following COVID-19 meeting on 11 November 2022
An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their meeting on 11 November 2022.
New COVID-19 variant leads to increase in cases
A statement from Professor Paul Kelly, Australian Government Chief Medical Officer, on the increase in COVID-19 cases due to a new Omicron variant.
ATAGI recommendations for a booster dose of the paediatric Pfizer COVID-19 vaccine in children aged 5 to 11 years
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on Pfizer booster doses for children aged 5 to 11 years.
ATAGI recommend the COVID-19 vaccination for some children aged 6 months to under 5 years
Australia’s immunisation experts, the Australian Technical Advisory Group on Immunisation, recommend COVID-19 vaccination for some children aged 6 months to under 5 years who have an increased risk of getting very sick from COVID-19. The COVID-19 vaccination will help reduce this risk.
ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine
A statement from the Australian Technical Advisory Group on Immunisation (ATAGI) regarding COVID-19 Moderna Spikevax Bivalent Original/Omicron BA.1 vaccine.
AHPPC Statement – reduced isolation period for COVID-19 cases
The Australian Health Protection Principal Committee (AHPPC) notes the need for a proportionate approach to isolation for those with COVID‑19 infections at this stage of the pandemic.
ATAGI update following weekly COVID-19 meeting – 31 August 2022
An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 31 August 2022.
National Cabinet Statement on COVID-19 settings
The following statement was released following the conclusion of National Cabinet on Wednesday 31 August 2022.
ATAGI update following weekly COVID-19 meeting – 24 August 2022
An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 24 August 2022.
Novavax vaccine for adolescents aged 12–17 years
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Novavax vaccine for adolescents aged 12-17 years.
Keep Your Spirit Strong
During COVID-19 many people face challenges that have impacted their mental health. The ‘Keep Your Spirit Strong’ project aims to help Aboriginal and Torres Strait Islanders take important steps to ensure they are prioritising their social and emotional wellbeing.
ATAGI recommends COVID-19 vaccine use in some children aged 6 months to 4 years
From 5 September 2022, the Australian Technical Advisory Group on Immunisation (ATAGI) recommends COVID-19 vaccination for children aged 6 months to 4 years who are severely immunocompromised, have a disability, or have complex and/or multiple health conditions.
ATAGI update following weekly COVID-19 meeting – 3 August 2022
An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 3 August 2022
ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) COVID-19 vaccine use in children.
ATAGI update following weekly COVID-19 meeting – 27 July 2022
An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 27 July 2022.
ATAGI update following weekly COVID-19 meeting – 20 July 2022
An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 20 July 2022.
COVID-19 update from the Chief Medical Officer, Professor Paul Kelly
A statement by Australia's Chief Medical Officer, Professor Paul Kelly regarding the increase in cases of the new BA.4 and BA.5 subvariants of the COVID-19 Omicron strain.
Date last updated: